Vincent O'Neill - Executive Vice President, Chief of Product Development and Medical Officer at BioXcel Therapeutics, Inc.

Issuer-level insider activity

Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by Vincent O'Neill since 12 Aug 2025

Reported holdings for Vincent O'Neill in BioXcel Therapeutics, Inc.

Form 4 holding Executive Vice President, Chief of Product Development and Medical Officer

BioXcel Therapeutics, Inc.

Security class
Common Stock
Shares / value
19,957
Estimated value
$7,031
Report date
16 Dec 2024
Price
$0.3523
Ownership
Direct
Form 4 holding Executive Vice President, Chief of Product Development and Medical Officer

BioXcel Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
2,606
Estimated value
$944
Report date
14 Dec 2024
Price
$0.3624
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Executive Vice President, Chief of Product Development and Medical Officer

BioXcel Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
1,875
Estimated value
Report date
22 Jul 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0

Transaction history for Vincent O'Neill in BioXcel Therapeutics, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .